Denileukin diftitox as novel targeted therapy for lymphoid malignancies

Cancer Investigation

Volumn 25, Issue 6, 2007, Pages 495-501

  Wong, Bryan Y ^a   Gregory, Stephanie A ^b   Dang, Nam H ^a  

^a NEVADA CANCER INSTITUTE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell lymphoma; CD25; Denileukin diftitox; IL 2 receptor; T cell lymphoma; Targeted therapy

Indexed keywords

BEXAROTENE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHENHYDRAMINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PARACETAMOL; STEROID; VANCOMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASTHENIA; B CELL LYMPHOMA; CANCER CELL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEART TAMPONADE; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPOSI SARCOMA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER DISEASE; LIVER TRANSAMINITIS; LUNG EMBOLISM; LYMPHOCYTOMA; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RASH; RECURRENT CANCER; REVIEW; SEZARY SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; T CELL LEUKEMIA; T LYMPHOCYTE; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOMA; MALE; RECOMBINANT FUSION PROTEINS;

EID: 34548839667     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701360096     Document Type: Review

References (41)

1. Lowenthal, J.W.; Zubler, R.H.; Nabholz, M.; MacDonald, H.R. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature 1985, 315 (6021), 669-672.
2. Waldmann, T.A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986, 232 (4751), 727-732.
3. Holter, W.; Goldman, C.K.; Casabo, L.; Nelson, D.L.; Greene, W.C.; Waldmann, T.A. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J. Immunol. 1987, 138 (9), 2917-2922.
4. Robb, R.J.; Rusk, C.M.; Yodoi, J.; Greene, W.C. Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc. Natl. Acad. Sci. USA 1987, 84 (7), 2002-2006.
5. Williams, D.P.; Parker, K.; Bacha, P.; Bishai, W.; Borowski, M.; Genbauffe, F.; Strom, T.B.; Murphy, J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987, 1 (6), 493-498.
6. Williams, D.P.; Snider, C.E.; Strom, T.B.; Murphy, J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990, 265 (20), 11885-11889.
7. Bacha, P.; Williams, D.P.; Waters, C.; Williams, J.M.; Murphy, J.R.; Strom, T.B. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J. Exp. Med. 1988, 167 (2), 612-622.
8. Waters, C.A.; Schimke, P.A.; Snider, C.E.; Itoh, K.; Smith, K.A.; Nichols, J.C.; Strom, T.B.; Murphy, J.R. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 1990, 20 (4), 785-791.
9. Bastos, M.G.; Pankewycz, O.; Rubin-Kelley, V.E.; Murphy, J.R.; Strom, T.B. Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen-activated T cell clones. J. Immunol. 1990, 145 (11), 3535-3539.
10. Balcer, L.J.; McIntosh, K.R.; Nichols, J.C.; Drachman, D.B. Suppression of immune responses to acetylcholine receptor by interleukin 2-fusion toxin: in vivo and in vitro studies. J. Neuroimmunol. 1991, 31 (2), 115-122.
11. Maslinski, W.; Murphy, J.R.; Strom, T.B. Intoxication of high affinity IL-2 receptor positive thymocytes blocks early stages of T cell maturation. Int. Immunol. 1992, 4 (4), 509-517.
12. Finberg, R.W.; Wahl, S.M.; Allen, J.B.; Soman, G.; Strom, T.B.; Murphy, J.R.; Nichols, J.C. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991, 252 (5013), 1703-1705.
13. Zhang, L.; Waters, C.; Nichols, J.; Crumpacker, C. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2. J Acquir Immune Defic Syndr 1992, 5 (12), 1181-1187.
14. Zhang, L.J.; Waters, C.A.; Poisson, L.R.; Estis, L.F.; Crumpacker, C.S. The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells. J. Infect. Dis. 1997, 175 (4), 790-794.
15. Pacheco-Silva, A.; Bastos, M.G.; Muggia, R.A.; Pankewycz, O.; Nichols, J.; Murphy, J.R.; Strom, T.B.; Rubin-Kelley, V.E. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur. J. Immunol. 1992, 22 (3), 697-6702.
16. Ramadan, M.A.; Gabr, N.S.; Bacha, P.; Gunzler, V.; Phillips, S.M. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy. Cell Immunol. 1995, 166 (2), 217-226.
17. Hullett, D.A.; Landry, A.S.; Eckoff, D.E.; Nichols, J.C.; Eugui, E.M.; Allison, A.C.; Sollinger, H.W. Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443. Transpl. Int. 1992, 5 (Suppl. 1), S487-S489.
18. Hullett, D.A.; Landry, A.S.; Eckhoff, D.E.; Nichols, J.C.; Eugui, E.M.; Allison, A.C.; Sollinger, H.W. DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival. Transplant Proc. 1993, 25 (1 Pt. 1), 756-757.
19. LeMaistre, C.F.; Meneghetti, C.; Rosenblum, M.; Reuben, J.; Parker, K.; Shaw, J.; Deisseroth, A.; Woodworth, T.; Parkinson, D.R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992, 79 (10), 2547-2554.
20. Kuzel, T.M.; Rosen, S.T.; Gordon, L.I.; Winter, J.; Samuelson, E.; Kaul, K.; Roenigk, H.H.; Nylen, P.; Woodworth, T. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk. Lymphoma 1993, 11 (5-6), 369-377.
21. Tepler, I.; Schwartz, G.; Parker, K.; Charette, J.; Kadin, M.E.; Woodworth, T.G.; Schnipper, L.E. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994, 73 (4), 1276-1285.
22. Foss, F.M.; Borkowski, T.A.; Gilliom, M.; Stetler-Stevenson, M.; Jaffe, E.S.; Figg, W.D.; Tompkins, A.; Bastian, A.; Nylen, P.; Woodworth, T.; et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994, 84 (6), 1765-1774.
23. LeMaistre, C.F.; Craig, F.E.; Meneghetti, C.; McMullin, B.; Parker, K.; Reuben, J.; Boldt, D.H.; Rosenblum, M.; Woodworth, T. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res. 1993, 53 (17), 3930-3934.
24. LeMaistre, C.F.; Saleh, M.N.; Kuzel, T.M.; Foss, F.; Platanias, L.C.; Schwartz, G.; Ratain, M.; Rook, A.; Freytes, C.O.; Craig, F.; Reuben, J.; Nichols, J.C. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998, 91 (2), 399-405.
25. Duvic, M.; Cather, J.; Maize, J.; Frankel, A.E. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am. J. Hematol. 1998, 58 (1), 87-90.
26. Olsen, E.; Duvic, M.; Frankel, A.; Kim, Y.; Martin, A.; et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 2001, 19 (2), 376-388.
27. Carretero-Margolis, C.D.; Fivenson, D.P. A complete and durable response to denileukin diftitox in a patient with mycosis fungoides. J. Am. Acad. Dermatol. 2003, 48 (2), 275-276.
28. Foss, F.M.; Bacha, P.; Osann, K.E.; Demierre, M.F.; Bell, T.; Kuzel, T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma 2001, 1 (4), 298-302.
29. Talpur, R.; Apisarnthanarax, N.; Ward, S.; Duvic, M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk. Lymphoma 2002, 43 (1), 121-126.
30. Di Venuti, G.; Nawgiri, R.; Foss, F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin. Lymphoma 2003, 4 (3), 176-178.
31. Dang, N.H.; Pro, B.; Hagemeister, F.B.; Samaniego, F.; Jones, D.; et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Brit. J. Hematology. 2007, 136 (3), 439-447.
32. Talpur, R.; Jones, D.M.; Alencar, A.J.; Apisarnthanarax, N.; Herne, K.L.; Yang, Y.; Duvic, M. CD25 expression is correlated with histological Grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J. Invest. Dermatol. 2006, 126 (3), 575-583.
33. Foss, F.; Demierre, M.F.; DiVenuti, G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106 (2), 454-457.
34. Gorgun, G.; Foss, F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002, 100 (4), 1399-1403.
35. Shao, R.H.; Tian, X.; Gorgun, G.; Urbano, A.G.; Foss, F.M. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk. Res. 2002, 26 (12), 1077-1083.
36. Ho, V.T.; Zahrieh, D.; Hochberg, E.; Micale, E.; Levin, J.; Reynolds, C.; Steckel, S.; Cutler, C.; Fisher, D.C.; Lee, S.J.; Alyea, E.P.; Ritz, J.; Soiffer, R.J.; Antin, J.H. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104 (4), 1224-1226.
37. Shaughnessy, P.J.; Bachier, C.; Grimley, M.; Freytes, C.O.; Callander, N.S.; Essell, J.H.; Flomenberg, N.; Selby, G.; Lemaistre, C.F. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol. Blood Marrow Transplant 2005, 11 (3), 188-193.
38. Paschal, B.R. Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy. Leuk. Lymphoma 2003, 44 (4), 731-733.
39. Dang, N.H.; Hagemeister, F.B.; Pro, B.; McLaughlin, P.; Romaguera, J.E.; et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2004, 22 (20), 4095-4102.
40. Frankel, A.E.; Fleming, D.R.; Hall, P.D.; Powell, B.L.; Black, J.H.; Leftwich, C.; Gartenhaus, R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res. 2003, 9 (10 Pt. 1), 3555-3561.
41. Dang, N.H.; McLaughlin, P.; Fayad, L.; Romaguera, J.E.; Hagemeister, F.B.; et al. Interim analysis of a phase II study of the combination of denileukin diftitox (Ontak) and rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Blood 2005, 106 (11), (Abstr. 3349).